Alnylam Pharmaceuticals (ALNY) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.

Which has better valuation & earnings, ALNY or RPRX?

Royalty Pharma has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$1.83B	10.33	-$440.24M	-$2.68	-55.71
Royalty Pharma	$2.36B	6.87	$1.13B	$1.34	20.22

Does the MarketBeat Community prefer ALNY or RPRX?

Alnylam Pharmaceuticals received 774 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.81% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1090 76.17%	Underperform Votes 341 23.83%
Royalty Pharma	Outperform Votes 316 67.81%	Underperform Votes 150 32.19%

Which has more volatility and risk, ALNY or RPRX?

Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Does the media prefer ALNY or RPRX?

In the previous week, Royalty Pharma had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 12 mentions for Royalty Pharma and 9 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.11 beat Royalty Pharma's score of 0.64 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ALNY or RPRX?

Alnylam Pharmaceuticals currently has a consensus price target of $216.19, suggesting a potential upside of 44.80%. Royalty Pharma has a consensus price target of $43.00, suggesting a potential upside of 58.73%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.59
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Is ALNY or RPRX more profitable?

Royalty Pharma has a net margin of 35.70% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Royalty Pharma's return on equity of 22.94% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-16.58%	N/A	-8.92%
Royalty Pharma	35.70%	22.94%	13.78%

Do insiders and institutionals have more ownership in ALNY or RPRX?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 18.9% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.